Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study

• Published in: Arthritis research & therapy Vol. 26; no. 1; pp. 67 - 7
• Main Authors: Li, Jun, Peng, Liying, Wu, Lijun, Ding, Yufang, Duan, Xinwang, Xu, Jian, Wei, Wei, Chen, Zhen, Zhao, Cheng, Yang, Min, Jiang, Nan, Zhang, Shangzhu, Wang, Qian, Tian, Xinping, Li, Mengtao, Zeng, Xiaofeng, Zhao, Yan, Zhao, Jiuliang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.03.2024; BioMed Central; BMC
• Subjects: Antibodies; Antiphospholipid antibodies; Blood platelets; Bone marrow; Care and treatment; Cohort analysis; Complications and side effects; Development and progression; Hematology; Laboratories; Leukemia; Lupus; Medical prognosis; Prognosis; Rheumatology; Risk factors; Severity; Systemic Lupus Erythematosus; Testing; Thrombocytopenia; China; United States > US; Germany; Systemic Lupus Erythematosus; Thrombocytopenia; Severity; Prognosis; Antiphospholipid antibodies

To investigate the role of antiphospholipid antibodies (aPLs) in the disease severity and prognosis of SLE-related thrombocytopenia (SLE-TP). This multicenter prospective study was conducted based on data from the CSTAR registry. TP was defined as a platelet count<100 × 10 /L. Demographic charact...